Home » Stocks » EQ

Equillium, Inc. (EQ)

Stock Price: $7.05 USD -0.54 (-7.11%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
Market Cap 204.73M
Revenue (ttm) n/a
Net Income (ttm) -28.46M
Shares Out 21.37M
EPS (ttm) -1.54
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $7.05
Previous Close $7.59
Change ($) -0.54
Change (%) -7.11%
Day's Open 7.35
Day's Range 6.93 - 7.73
Day's Volume 479,340
52-Week Range 2.20 - 27.05

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 2 weeks ago

Higher dose cohorts demonstrated 100% overall response rate, resulting in substantial  reduction in baseline corticosteroid use

GlobeNewsWire - 2 weeks ago

LA JOLLA, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disord...

GlobeNewsWire - 3 weeks ago

LA JOLLA, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disord...

Benzinga - 3 weeks ago

GlobeNewsWire - 3 weeks ago

LA JOLLA, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disord...

GlobeNewsWire - 1 month ago

LA JOLLA, Calif., Jan. 22, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disord...

GlobeNewsWire - 2 months ago

Studies further support itolizumab's potential as treatment for aGVHD patients Studies further support itolizumab's potential as treatment for aGVHD patients

Zacks Investment Research - 3 months ago

Equillium (EQ) decides to not initiate a phase III study on its candidate, itolizumab, for the treatment of hospitalized COVID-19 patients at this time.

Market Watch - 3 months ago

Shares of Equillium Inc. tumbled 12.6% in premarket trading Wednesday, after the biotechnology company said it decided not to initiate a Phase 3 trial its itolizumab for the treatment of hospi...

GlobeNewsWire - 3 months ago

Analyst Day scheduled for December 4, 2020 Analyst Day scheduled for December 4, 2020

GlobeNewsWire - 3 months ago

LA JOLLA, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disor...

GlobeNewsWire - 3 months ago

LA JOLLA, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disor...

GlobeNewsWire - 3 months ago

100% overall response rate in dose cohort 3 and 80% overall response rate across all cohorts to date

GlobeNewsWire - 3 months ago

Studies  further validate  ongoing clinical  development of itolizumab for the treatment  of  systemic  lupus   erythematosus and lupus  nephritis

InvestorPlace - 4 months ago

Equillium (EQ) stock is seeing gains on Friday after getting the go-ahead from the FDA for a drug trial treating the coronavirus. The post EQ Stock: 6 Things to Know about Biotech Company Equi...

24/7 Wall Street - 4 months ago

Equillium Inc. (NASDAQ: EQ) shares jumped on Friday after the company announced a key update from the U.S.

GlobeNewsWire - 4 months ago

Equillium p lans to initiate global Phase 3 COVID-19 trial – EQUINOX – during Q4  2020

Zacks Investment Research - 4 months ago

Is (EQ) Outperforming Other Medical Stocks This Year?

GlobeNewsWire - 5 months ago

LA JOLLA, Calif., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory di...

GlobeNewsWire - 5 months ago

Equillium anticipates filing a U.S. IND for Itolizumab for COVID-19 and initiating a global Phase 3 clinical study in Q4 2020

GlobeNewsWire - 5 months ago

LA JOLLA, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel pr...

GlobeNewsWire - 6 months ago

LA JOLLA, Calif., Aug. 18, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory dis...

GlobeNewsWire - 6 months ago

LA JOLLA, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory dis...

GlobeNewsWire - 6 months ago

LA JOLLA, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory dis...

GlobeNewsWire - 6 months ago

LA JOLLA, Calif., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory dis...

GlobeNewsWire - 6 months ago

Complete response observed in five of seven patients in first two dose cohorts

GlobeNewsWire - 7 months ago

LA JOLLA, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel pro...

InvestorPlace - 7 months ago

Equillium (EQ) news for Tuesday concerning a deal with Jefferies (JEF) to sell shares of EQ stock has it falling on Tuesday. The post Equillium News: Why EQ Stock Is Plummeting 46% Today appea...

Zacks Investment Research - 7 months ago

Equillium (EQ) soars on positive results on pipeline candidate, itolizumab, for COVID-19.

GlobeNewsWire - 7 months ago

Equillium shares topline results of patients treated with itolizumab in clinical trial conducted in India by partner Biocon

GlobeNewsWire - 9 months ago

LA JOLLA, Calif., May 13, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to ...

GlobeNewsWire - 11 months ago

LA JOLLA, Calif., March 30, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products t...

GlobeNewsWire - 11 months ago

EQUIP and EQUALISE Studies to be Paused in Response to the COVID-19 Pandemic

GlobeNewsWire - 1 year ago

Maple Fung, M.D., joins as vice president clinical development Matthew Ritter, Ph.D., joins as vice president corporate development

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor in Equillium.

Zacks Investment Research - 1 year ago

Equillium has been struggling lately, but the selling pressure may be coming to an end soon.

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor Equillium

GlobeNewsWire - 1 year ago

LA JOLLA, Calif. and BENGALURU, India, Dec. 12, 2019 (GLOBE NEWSWIRE) -- Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology ...

GlobeNewsWire - 1 year ago

LA JOLLA, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products ...

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor Equillium.

GlobeNewsWire - 1 year ago

LA JOLLA, Calif., Nov. 15, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products ...

GlobeNewsWire - 1 year ago

Effective January 1, 2020 Bruce Steel will assume role of Chief Executive Officer, and  Dan Bradbury will remain on the Board of Directors as Executive Chairman

GlobeNewsWire - 1 year ago

Company secures up to $20 million debt facility with Silicon Valley Bank and Oxford Finance LLC

GlobeNewsWire - 1 year ago

LA JOLLA, Calif., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company, leveraging deep understanding of immunobiology to develop products ...

GlobeNewsWire - 1 year ago

LA JOLLA, Calif., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to...

About EQ

Equillium, a clinical-stage biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its... [Read more...]

Industry
Biotechnology
IPO Date
Oct 11, 2018
CEO
Bruce Steel
Employees
26
Stock Exchange
NASDAQ
Ticker Symbol
EQ
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for Equillium stock is "Strong Buy." The 12-month stock price forecast is 16.25, which is an increase of 130.50% from the latest price.

Price Target
$16.25
(130.50% upside)
Analyst Consensus: Strong Buy